FDA panel to consider simplifying COVID-19 vaccine use

A Food and Drug Administration advisory committee is scheduled to vote Thursday on whether to simplify current COVID-19 vaccine use so that all primary series and booster doses administered in the U.S. would be bivalent. The committee also is expected to discuss simplifying future COVID-19 vaccine use to authorize or approve a two-dose series for certain young children, older adults and people with compromised immunity and only one dose for all other individuals; as well as periodic updates to COVID-19 vaccines, including for use this fall.